Description: A Phase 1, First-In-Human Study of IK-930, An oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
Mechanism of Action: TEAD Inhibitor Targeting the Hippo Pathway. Markers of aberrant Hippo pathway include YAP/TAZ gene alterations or NF2 loss of function mutations/deletions. Cancers of special interest include – malignant pleural mesothelioma, epithelial hemangioendothelioma regardless of above mutational markers.
Target Patient Population: All solid tumors
Study Design: Study Drug is given orally.